SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy (2022)
- Authors:
- USP affiliated authors: SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1093/rheumatology/keab886
- Subjects: PEDIATRIA; DOENÇAS NEONATAIS E ANORMALIDADES; ANTIBIÓTICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Rheumatology
- ISSN: 1462-0324
- Volume/Número/Paginação/Ano: v. 61, n. SI2, suppl.I2, Special Issue, p. SI169-SI174, 2022
- Status:
- Artigo possui acesso gratuito no site do editor (Bronze Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SAMPAIO-BARROS, Percival Degrava et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, v. 61, n. SI2, p. SI169-SI174, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab886. Acesso em: 02 abr. 2026. -
APA
Sampaio-Barros, P. D., Medeiros-Ribeiro, A. C., Luppino-Assad, A. P., Miossi, R., Silva, H. C. da, Yuki, E. F. V. N., et al. (2022). SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. Rheumatology, 61( SI2), SI169-SI174. doi:10.1093/rheumatology/keab886 -
NLM
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1093/rheumatology/keab886 -
Vancouver
Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Silva HC da, Yuki EFVN, Pasoto SG, Saad CGS, Silva CAA da, Kupa L de VK, Bonfa ESD de O. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy [Internet]. Rheumatology. 2022 ; 61( SI2): SI169-SI174.[citado 2026 abr. 02 ] Available from: https://doi.org/10.1093/rheumatology/keab886 - Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Lupus nephritis-related issues during COVID-19 pandemic quarantine
- Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus
- High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting
- Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country
- 23-valent polysaccharice pneumococcal vaccine in juvenile idiopathic arthritis patients: anti-tumor necrosis factor therapy role in short and long-term immunogenicity
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
